SCHEDULE 13G: Coastlands Capital Discloses 9.3% Stake in AN2 Therapeutics
Beneficial Ownership Disclosure
Coastlands Capital LP and its affiliated entities have disclosed a passive beneficial ownership of 9.3% of AN2 Therapeutics, Inc.'s common stock.
Summary
- Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry have jointly filed a Schedule 13G.
- The reporting persons collectively beneficially own 2,815,900 shares of AN2 Therapeutics, Inc. Common Stock.
- This ownership represents 9.3% of the total outstanding Common Stock of AN2 Therapeutics, Inc.
- The percentage is calculated based on 30,175,720 shares of Common Stock outstanding as of May 5, 2025, as reported in the Issuer's Form 10-Q for the quarter ended March 31, 2025.
- Coastlands Capital LP and Coastlands Capital GP LLC serve as the investment adviser and general partner, respectively, of Coastlands Capital Partners LP.
- Coastlands Capital LLC is the general partner of Coastlands Capital LP, and Matthew D. Perry is the control person of Coastlands Capital, Coastlands Capital GP LLC, and Coastlands Capital LLC.
- The filing indicates shared voting and dispositive power over the 2,815,900 shares for most reporting persons, with Coastlands Capital GP LLC having sole voting and dispositive power.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment in AN2 Therapeutics, a biotechnology company. Such disclosures are common in the biotech sector as investment firms take positions in companies with promising pipelines or market potential.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by Coastlands Capital may be viewed positively, signaling confidence in AN2 Therapeutics by a professional investment firm.
Key Dates
| Date | Description |
|---|---|
| 2025-03-31 | End of quarter for which AN2 Therapeutics, Inc. filed its Form 10-Q, reporting shares outstanding. |
| 2025-05-05 | Date on which 30,175,720 shares of Common Stock were reported outstanding by AN2 Therapeutics, Inc. |
| 2025-05-28 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-06-04 | Date of signing for the Schedule 13G filing and the Joint Filing Agreement. |
Keywords
AN2 Therapeutics, Coastlands Capital, Schedule 13G, Beneficial Ownership, Common Stock, Investment Firm, SEC Filing, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.